An FDA Advisory Panel met on September 17-18 to evaluate the benefits and risks of prescription testosterone supplements, including AndroGel, Axiron, Fortesta and other drugs in this class. The Panel concluded that there is insufficient evidence to support the manufacturers’ claims that the supplements treat diminishing testosterone levels. The Panel also recommended further study of the risks of heart attack, stroke, pulmonary embolism and death, with an eye towards a potential label change. The websites www.AndrogelLawyers.com and www.levenstenlawfirm.com discuss in detail studies which show an increased risk of these events by nearly 30% in some men. As evidence of the manufacturers’ concern, the AndroGel ads went from ever present to non-existent as it appears they’ve been pulled indefinitely.

Nearly 2.3 million people took prescription testosterone last year. The numbers would have risen had not people like the Levensten Law Firm jumped out front in communicating the risks to potential victims when the evidence appeared in scientific journals. The manufacturers of AndroGel and other products would have kept on over-promoting, and stayed silent about the risks which would have killed their blockbuster products. The manufacturers failure to warn of these risks is now the subject of Multi-district litigation in Illinois federal court, and expected to comprise thousands of serious injury cases.

Please feel free to contact us through this site or www.levenstenlawfirm.com for more information about the litigation and protecting your rights to compensation.